University of Hertfordshire

From the same journal

By the same authors

Is There a Potential of Misuse for Quetiapine?

Research output: Contribution to journalReview articlepeer-review

Standard

Is There a Potential of Misuse for Quetiapine? / Chiappini, Stefania; Schifano, Fabrizio.

In: Journal of Clinical Psychopharmacology, Vol. 38, No. 1, 01.02.2018, p. 72-79.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{bb0419f4859b46f7adf3e926230186e9,
title = "Is There a Potential of Misuse for Quetiapine?",
abstract = "Purpose/Background A recent years' increase in both prescribing and availability of second-generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine seems to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA that has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse. Hence, while providing here an updated literature review of the topic, we aimed at assessing all cases of quetiapine misuse/abuse/dependence/withdrawal as reported to the European Medicines Agency's EudraVigilance (EV) database; this was carried out in comparison with the reference drug olanzapine. Methods All spontaneous, European Medicines Agency database reports relating to both quetiapine (2005-2016) and olanzapine (2004-2016) misuse/abuse/dependence/withdrawal issues were retrieved, and a descriptive analysis was performed. Results From the EV database, 18,112 (8.64% of 209,571) and 4178 (7.58% of 55,100) adverse drug reaction reports of misuse/abuse/dependence/withdrawal were associated with quetiapine and olanzapine, respectively. The resulting proportional reporting ratio values suggested that the misuse/abuse-, dependence-, and withdrawal-related adverse drug reactions were more frequently reported for quetiapine (1.07, 1.01, and 5.25, respectively) in comparison with olanzapine. Conclusions Despite data collection limitations, present EV data may suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern.",
keywords = "drug misuse, European Medicines Agency, olanzapine, pharmacovigilance, quetiapine",
author = "Stefania Chiappini and Fabrizio Schifano",
note = "This document is the Accepted Manuscript version. Under embargo until 28 February 2019. Reprinted from Journal of Clinical Psychopharmacology, Vol. 31(1): 72-79, February 2018, with permission of Kluwer Law International.",
year = "2018",
month = feb,
day = "1",
doi = "10.1097/JCP.0000000000000814",
language = "English",
volume = "38",
pages = "72--79",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Is There a Potential of Misuse for Quetiapine?

AU - Chiappini, Stefania

AU - Schifano, Fabrizio

N1 - This document is the Accepted Manuscript version. Under embargo until 28 February 2019. Reprinted from Journal of Clinical Psychopharmacology, Vol. 31(1): 72-79, February 2018, with permission of Kluwer Law International.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose/Background A recent years' increase in both prescribing and availability of second-generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine seems to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA that has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse. Hence, while providing here an updated literature review of the topic, we aimed at assessing all cases of quetiapine misuse/abuse/dependence/withdrawal as reported to the European Medicines Agency's EudraVigilance (EV) database; this was carried out in comparison with the reference drug olanzapine. Methods All spontaneous, European Medicines Agency database reports relating to both quetiapine (2005-2016) and olanzapine (2004-2016) misuse/abuse/dependence/withdrawal issues were retrieved, and a descriptive analysis was performed. Results From the EV database, 18,112 (8.64% of 209,571) and 4178 (7.58% of 55,100) adverse drug reaction reports of misuse/abuse/dependence/withdrawal were associated with quetiapine and olanzapine, respectively. The resulting proportional reporting ratio values suggested that the misuse/abuse-, dependence-, and withdrawal-related adverse drug reactions were more frequently reported for quetiapine (1.07, 1.01, and 5.25, respectively) in comparison with olanzapine. Conclusions Despite data collection limitations, present EV data may suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern.

AB - Purpose/Background A recent years' increase in both prescribing and availability of second-generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine seems to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA that has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse. Hence, while providing here an updated literature review of the topic, we aimed at assessing all cases of quetiapine misuse/abuse/dependence/withdrawal as reported to the European Medicines Agency's EudraVigilance (EV) database; this was carried out in comparison with the reference drug olanzapine. Methods All spontaneous, European Medicines Agency database reports relating to both quetiapine (2005-2016) and olanzapine (2004-2016) misuse/abuse/dependence/withdrawal issues were retrieved, and a descriptive analysis was performed. Results From the EV database, 18,112 (8.64% of 209,571) and 4178 (7.58% of 55,100) adverse drug reaction reports of misuse/abuse/dependence/withdrawal were associated with quetiapine and olanzapine, respectively. The resulting proportional reporting ratio values suggested that the misuse/abuse-, dependence-, and withdrawal-related adverse drug reactions were more frequently reported for quetiapine (1.07, 1.01, and 5.25, respectively) in comparison with olanzapine. Conclusions Despite data collection limitations, present EV data may suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern.

KW - drug misuse

KW - European Medicines Agency

KW - olanzapine

KW - pharmacovigilance

KW - quetiapine

UR - http://www.scopus.com/inward/record.url?scp=85040320623&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000814

DO - 10.1097/JCP.0000000000000814

M3 - Review article

VL - 38

SP - 72

EP - 79

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -